Integral Health Asset Management LLC Takes Position in Ascendis Pharma A/S $ASND

Integral Health Asset Management LLC purchased a new position in Ascendis Pharma A/S (NASDAQ:ASND) during the 3rd quarter, Holdings Channel reports. The firm purchased 60,000 shares of the biotechnology company’s stock, valued at approximately $11,929,000.

A number of other large investors have also made changes to their positions in the stock. Jones Financial Companies Lllp lifted its position in shares of Ascendis Pharma A/S by 57.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 83 shares during the period. Quadrant Capital Group LLC acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at $74,000. Farther Finance Advisors LLC lifted its holdings in shares of Ascendis Pharma A/S by 115.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 478 shares of the biotechnology company’s stock worth $95,000 after acquiring an additional 256 shares during the period. Toth Financial Advisory Corp boosted its position in shares of Ascendis Pharma A/S by 33.7% during the 3rd quarter. Toth Financial Advisory Corp now owns 595 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 150 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of Ascendis Pharma A/S by 15.2% during the 3rd quarter. GAMMA Investing LLC now owns 735 shares of the biotechnology company’s stock valued at $146,000 after acquiring an additional 97 shares in the last quarter.

Wall Street Analysts Forecast Growth

ASND has been the subject of a number of recent research reports. Wolfe Research reissued an “outperform” rating and issued a $260.00 target price on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $300.00 target price on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. Wedbush increased their target price on shares of Ascendis Pharma A/S from $240.00 to $273.00 and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Stifel Nicolaus set a $332.00 target price on Ascendis Pharma A/S in a report on Wednesday, March 4th. Finally, Wall Street Zen lowered Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and an average price target of $289.88.

Ascendis Pharma A/S Price Performance

ASND stock opened at $225.98 on Friday. The company has a 50 day moving average price of $224.24 and a 200 day moving average price of $211.10. Ascendis Pharma A/S has a fifty-two week low of $124.06 and a fifty-two week high of $248.60. The stock has a market capitalization of $14.01 billion, a PE ratio of -51.36 and a beta of 0.43.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, February 11th. The biotechnology company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.58). The business had revenue of $290.38 million during the quarter, compared to analysts’ expectations of $285.35 million. As a group, equities analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.